Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Randomized, Phase 2A, Dose-Ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens

NCT01284348 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT01284348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01284348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Randomized, Phase 2A, Dose-Ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 2
Overall status
Terminated
Start date
March 25, 2011
Completion date
September 21, 2012
Enrollment
26 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, bladder cancer, cancer of head and neck, carcinoma, non-small-cell lung, carcinoma, small-cell lung, uterine cervical cancer